Expression and role of p53 in the retina

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 3, 2012, Pages 1362-1371

  Vuong, Linda ^a   Conley, Shannon M ^a   Al Ubaidi, Muayyad R ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL ACETYLTRANSFERASE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P21; PROTEIN P53; PROTEIN P63; PROTEIN P73; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR YY1; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; EYE DEVELOPMENT; GENE MUTATION; HOMEOSTASIS; HUMAN; IONIZING RADIATION; LIGHT EXPOSURE; NERVE CELL DIFFERENTIATION; NONHUMAN; OXIDATIVE STRESS; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; RETINOBLASTOMA; STEM CELL; ANIMAL; CELL CYCLE; DISEASE MODEL; LIGHT; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; RETINA DISEASE; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CELL CYCLE; DISEASE MODELS, ANIMAL; E2F TRANSCRIPTION FACTORS; GENES, P53; HUMANS; LIGHT; MICE; OXIDATIVE STRESS; RETINA; RETINAL DISEASES; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860575052     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8909     Document Type: Article

References (147)

1. Linzer DI, Maltzman W, Levine AJ. The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology. 1979;98(2):308-318.
2. Wolf D, Rotter V. Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences. Mol Cell Biol. 1984;4(7):1402-1410.
3. Ben DY, Prideaux VR, Chow V, Benchimol S, Bernstein A. Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus. Oncogene. 1988;3(2):179-185.
4. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature. 1985;314(6012):633-636.
5. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A. 1985;82(3):790-794.
6. Eliyahu D, Goldfinger N, Pinhasi-Kimhi O, et al. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene. 1988;3(3):313-321.
7. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered halflife. Mol Cell Biol. 1988;8(2):531-539.
8. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A. 1989;86(22):8763-8767.
9. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57(7):1083-1093.
10. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 1990;62(4):671-680.
11. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
12. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-1238.
13. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348(6303):747-749.
14. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol. 2000;20(9):3224-3233.
15. Liang SH, Clarke MF. Regulation of p53 localization. Eur J Biochem. 2001;268(10):2779-2783.
16. Jayaraman L, Prives C. Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci. 1999;55(1):76-87.
17. Boehme KA, Blattner C. Regulation of p53-insights into a complex process. Crit Rev Biochem Mol Biol. 2009;44(6):367-392.
18. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol. 2009;1(6):a000950.
19. O'Brate A, Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat. 2003;6(6): 313-322.
20. Wang P, Reed M, Wang Y, et al. p53 domains: structure, oligomerization, and transformation. Mol Cell Biol. 1994;14(8):5182-5191.
21. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol. 1994;1(12):877-890.
22. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51(23 Pt 1):6304-6311.
23. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992; 358(6381):15-16.
24. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20(15):1803-1815.
25. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A. 1995;92(18):8493-8497.
26. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817-825.
27. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993; 366(6456):701-704.
28. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1(8):639-649.
29. Niculescu AB, III, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998;18(1):629-643.
30. Ogryzko VV, Wong P, Howard BH. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol. 1997;17(8):4877-4882.
31. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994;76(6):1013-1023.
32. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995;82(4):675-684.
33. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 1995;377(6549):552-557.
34. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 2000;12(6): 676-684.
35. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008; 8(6):450-458.
36. Kong Y, Cui H, Ramkumar C, Zhang H. Regulation of senescence in cancer and aging. J Aging Res. 2011;2011:963172.
37. Soria G, Speroni J, Podhajcer OL, Prives C, Gottifredi V. p21 differentially regulates DNA replication and DNA-repair-associated processes after UV irradiation. J Cell Sci. 2008;121(Pt 19): 3271-3282.
38. Gottifredi V, McKinney K, Poyurovsky MV, Prives C. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J Biol Chem. 2004;279(7):5802-5810.
39. van Gijssel HE, Leil TA, Weinberg WC, Divi RL, Olivero OA, Poirier MC. Cisplatin-DNA damage in p21WAF1/Cip1 deficient mouse keratinocytes exposed to cisplatin. Mutagenesis. 2007; 22(1):49-54.
40. Oku T, Ikeda S, Sasaki H, et al. Functional sites of human PCNA which interact with p21 (Cip1/Waf1), DNA polymerase delta and replication factor C. Genes Cells. 1998;3(6):357-369.
41. Podust VN, Podust LM, Goubin F, Ducommun B, Hubscher U. Mechanism of inhibition of proliferating cell nuclear antigendependent DNA synthesis by the cyclin-dependent kinase inhibitor p21. Biochemistry. 1995;34(27):8869-8875.
42. Chen U, Chen S, Saha P, Dutta A. p21Cip1/Waf1 disrupts the recruitment of human Fen1 by proliferating-cell nuclear antigen into the DNA replication complex. Proc Natl Acad Sci U S A. 1996;93(21):11597-11602.
43. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature. 1995;374(6520):386-388.
44. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352(6333):345-347.
45. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594-604.
46. Arima Y, Nitta M, Kuninaka S, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem. 2005;280(19):19166-19176.
47. Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death Differ. 2006;13(8):1256-1259.
48. Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria: a potential role in apoptotic signaling. J Biol Chem. 2000;275(21):16202-16212.
49. Thiersch M, Raffelsberger W, Frigg E, et al. The hypoxic transcriptome of the retina: identification of factors with potential neuroprotective activity. Adv Exp Med Biol. 2008;613:75-85.
50. Achison M, Hupp TR. Hypoxia attenuates the p53 response to cellular damage. Oncogene. 2003;22(22):3431-3440.
51. Pearson BJ, Sanchez AA. A planarian p53 homolog regulates proliferation and self-renewal in adult stem cell lineages. Development. 2010;137(2):213-221.
52. Cicalese A, Bonizzi G, Pasi CE, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell. 2009;138(6):1083-1095.
53. Senoo M, Pinto F, Crum CP, McKeon F. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell. 2007;129(3):523-536.
54. Liu Y, Elf SE, Miyata Y, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4(1):37-48.
55. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 2010;29(15):2659-2674.
56. Zhao Z, Zuber J, Diaz-Flores E, et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010;24(13):1389-1402.
57. Wang YV, Leblanc M, Fox N, et al. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev. 2011;25(13): 1426-1438.
58. Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell. 2010;6(4):309-322.
59. Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol. 2010;8(3):e1000324.
60. Mitsui K, Tokuzawa Y, Itoh H, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003;113(5):631-642.
61. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237-1245.
62. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet. 1987;13(3):235-244.
63. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991;10(6):1565-1569.
64. Maki CG. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem. 1999;274(23):16531-16535.
65. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420(1): 25-27.
66. Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH. C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol. 2001;21(24):8521-8532.
67. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A. 1993;90(24):11623-11627.
68. Shvarts A, Steegenga WT, Riteco N, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996;15(19):5349-5357.
69. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem. 1999;274(53):38189-38196.
70. Mancini F, Di CG, Monti O, et al. Puzzling over MDM4-p53 network. Int J Biochem Cell Biol. 2010;42(7):1080-1083.
71. Gu J, Kawai H, Nie L, et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem. 2002;277(22):19251-19254.
72. Mancini F, Di CG, Pellegrino M, et al. MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J. 2009;28(13):1926-1939.
73. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell. 2008;133(4):612-626.
74. Shi Y, Seto E, Chang LS, Shenk T. Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 1991;67(2):377-388.
75. Shi Y, Lee JS, Galvin KM. Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta. 1997;1332(2): F49-F66.
76. Krippner-Heidenreich A, Walsemann G, Beyrouthy MJ, et al. Caspase-dependent regulation and subcellular redistribution of the transcriptional modulator YY1 during apoptosis. Mol Cell Biol. 2005;25(9):3704-3714.
77. Yang WM, Inouye C, Zeng Y, Bearss D, Seto E. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sci U S A. 1996;93(23):12845-12850.
78. Gronroos E, Terentiev AA, Punga T, Ericsson J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci U S A. 2004;101(33):12165-12170.
79. Iyer NG, Chin SF, Ozdag H, et al. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci U S A. 2004; 101(19):7386-7391.
80. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997;387(6635):823-827.
81. Grossman SR, Perez M, Kung AL, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell. 1998; 2(4):405-415.
82. Sui G, Affar EB, Shi Y, et al. Yin Yang 1 is a negative regulator of p53. Cell. 2004;117(7):859-872.
83. Lohmann D. Retinoblastoma. Adv Exp Med Biol. 2010;685:220-227.
84. Wallace VA. Cancer biology: second step to retinal tumours. Nature. 2006;444(7115):45-46.
85. Sidle A, Palaty C, Dirks P, et al. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation. Crit Rev Biochem Mol Biol. 1996;31(3): 237-271.
86. Dyer MA, Bremner R. The search for the retinoblastoma cell of origin. Nat Rev Cancer. 2005;5(2):91-101.
87. Johnston AJ, Matveeva E, Kirioukhova O, Grossniklaus U, Gruissem W. A dynamic reciprocal RBR-PRC2 regulatory circuit controls Arabidopsis gametophyte development. Curr Biol. 2008; 18(21):1680-1686.
88. Wildwater M, Campilho A, Perez-Perez JM, et al. The retinoblastoma-related gene regulates stem cell maintenance in Arabidopsis roots. Cell. 2005;123(7):1337-1349.
89. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer. 2009;9(10):738-748.
90. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365(6444):349-352.
91. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006;444(7115):61-66.
92. Langheinrich U, Hennen E, Stott G, Vacun G. Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol. 2002;12(23):2023-2028.
93. Berghmans S, Murphey RD, Wienholds E, et al. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A. 2005;102(2):407-412.
94. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental abnormalities in p53-deficient mice. Curr Biol. 1995;5(8):931-936.
95. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 1995;10(2):175-180.
96. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398(6729):708-713.
97. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398(6729):714-718.
98. Bakkers J, Hild M, Kramer C, Furutani-Seiki M, Hammerschmidt M. Zebrafish DeltaNp63 is a direct target of Bmp signaling and encodes a transcriptional repressor blocking neural specification in the ventral ectoderm. Dev Cell. 2002;2(5):617-627.
99. Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell. 2002;2(5):607-616.
100. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404(6773):99-103.
101. Rentzsch F, Kramer C, Hammerschmidt M. Specific and conserved roles of TAp73 during zebrafish development. Gene. 2003; 323:19-30.
102. Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. Direct involvement of p53 in programmed cell death of oligodendrocytes. EMBO J. 1995;14(6):1136-1144.
103. Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M. p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol. 1996;16(9):5178-5185.
104. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4(1):1-7.
105. Reichel MB, Ali RR, D'Esposito F, et al. High frequency of persistent hyperplastic primary vitreous and cataracts in p53-deficient mice. Cell Death Differ. 1998;5(2):156-162.
106. Ikeda S, Hawes NL, Chang B, Avery CS, Smith RS, Nishina PM. Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice. Invest Ophthalmol Vis Sci. 1999;40(8):1874-1878.
107. Xu X, Quiambao AB, Roveri L, et al. Degeneration of cone photoreceptors induced by expression of the Mas1 protooncogene. Exp Neurol. 2000;163(1):207-219.
108. Cepko CL, Austin CP, Yang X, Alexiades M, Ezzeddine D. Cell fate determination in the vertebrate retina. 1996 Proc Natl Acad Sci U S A. 1996;93(2):589-595.
109. Young RW. Cell differentiation in the retina of the mouse. Anat Rec. 1985;212(2):199-205.
110. Young RW. Cell death during differentiation of the retina in the mouse. J Comp Neurol. 1984;229(3):362-373.
111. Tendler Y, Weisinger G, Coleman R, et al. Tissue-specific p53 expression in the nervous system. Brain Res Mol Brain Res. 1999;72(1):40-46.
112. Shin DH, Lee HY, Lee HW, et al. In situ localization of p53, bcl-2 and bax mRNAs in rat ocular tissue. Neuroreport. 1999;10(10): 2165-2167.
113. Noell WK, Walker VS, Kang BS, Berman S. Retinal damage by light in rats. Invest Ophthalmol. 1966;5(5):450-73.
114. Hansson HA. A histochemical study of cellular reactions in rat retina transiently damaged by visible light. Exp Eye Res. 1971; 12(3):270-274.
115. Westlund BS, Cai B, Zhou J, Sparrow JR. Involvement of c-Abl, p53 and the MAP kinase JNK in the cell death program initiated in A2E-laden ARPE-19 cells by exposure to blue light. Apoptosis. 2009;14(1):31-41.
116. Marti A, Hafezi F, Lansel N, et al. Light-induced cell death of retinal photoreceptors in the absence of p53. Invest Ophthalmol Vis Sci. 1998;39(5):846-849.
117. Lansel N, Hafezi F, Marti A, Hegi M, Reme C, Niemeyer G. The mouse ERG before and after light damage is independent of p53. Doc Ophthalmol. 1998;96(4):311-320.
118. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-471.
119. Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE. Fundus autofluorescence and development of geographic atrophy in agerelated macular degeneration. Invest Ophthalmol Vis Sci. 2001; 42(5):1051-1056.
120. von RA, Fitzke FW, Bird AC. Fundus autofluorescence in agerelated macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci. 1997;38(2):478-486.
121. Bhattacharya S, Ray RM, Chaum E, Johnson DA, Johnson LR. Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis. Invest Ophthalmol Vis Sci. 2011;52(6):3368-3380.
122. Borges HL, Chao C, Xu Y, Linden R, Wang JY. Radiation-induced apoptosis in developing mouse retina exhibits dose-dependent requirement for ATM phosphorylation of p53. Cell Death Differ. 2004;11(5):494-502.
123. Morgan SE, Kastan MB. p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res. 1997;71:1-25.
124. Borges HL, Linden R. Gamma irradiation leads to two waves of apoptosis in distinct cell populations of the retina of newborn rats. J Cell Sci. 1999;112 (Pt 23):4315-4324.
125. Wiegand RD, Giusto NM, Rapp LM, Anderson RE. Evidence for rod outer segment lipid peroxidation following constant illumination of the rat retina. Invest Ophthalmol Vis Sci. 1983;24(10): 1433-1435.
126. Organisciak DT, Darrow RM, Barsalou L, et al. Light history and age-related changes in retinal light damage. Invest Ophthalmol Vis Sci. 1998;39(7):1107-1116.
127. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45(2):115-134.
128. Yildirim O, Ates NA, Ercan B, et al. Role of oxidative stress enzymes in open-angle glaucoma. Eye (Lond). 2005;19(5):580-3.
129. Bhuyan KC, Bhuyan DK. Molecular mechanism of cataractogenesis: III. Toxic metabolites of oxygen as initiators of lipid peroxidation and cataract. Curr Eye Res. 1984;3(1):67-81.
130. Santosa S, Jones PJ. Oxidative stress in ocular disease: does lutein play a protective role? CMAJ. 2005;173(8):861-862.
131. Breider MA, Ulloa HM, Pegg DG, Gough AW. Nitro-imidazole radiosensitizer-induced toxicity in cynomolgus monkeys. Toxicol Pathol. 1998;26(5):651-656.
132. Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol. 2000;163(1):50-59.
133. Miller TJ, Schneider RJ, Miller JA, et al. Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3. Neurotoxicology. 2006;27(1):44-59.
134. O'Connor JC, Wallace DM, O'Brien CJ, Cotter TG. A novel antioxidant function for the tumor-suppressor gene p53 in the retinal ganglion cell. Invest Ophthalmol Vis Sci. 2008;49(10):4237-4244.
135. Joo CK, Choi JS, Ko HW, et al. Necrosis and apoptosis after retinal ischemia: involvement of NMDA-mediated excitotoxicity and p53. Invest Ophthalmol Vis Sci. 1999;40(3):713-720.
136. Rosenbaum DM, Rosenbaum PS, Gupta H, et al. The role of the p53 protein in the selective vulnerability of the inner retina to transient ischemia. Invest Ophthalmol Vis Sci. 1998;39(11): 2132-2139.
137. Kaur C, Foulds WS, Ling EA. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol. 2008;2(4):879-889.
138. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2004;23(1):91-147.
139. Pagon RA, Daiger SP. Retinitis pigmentosa overview. In: Pagon RS, Bird TD, Dolan CR, Stephens K, eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993-2002 [updated September 16, 2005].
140. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1:40.
141. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res. 2010;29(5):335-375.
142. Pittler SJ, Baehr W. Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodiesterase beta-subunit gene of the rd mouse. Proc Natl Acad Sci U S A. 1991;88(19): 8322-8326.
143. Hopp RM, Ransom N, Hilsenbeck SG, Papermaster DS, Windle JJ. Apoptosis in the murine rd1 retinal degeneration is predominantly p53-independent. Mol Vis. 1998;4:5.
144. Wu J, Trogadis J, Bremner R. Rod and cone degeneration in the rd mouse is p53 independent. Mol Vis. 2001;7:101-106.
145. Yoshizawa K, Kuwata M, Kawanaka A, Uehara N, Yuri T, Tsubura A. N-methyl-N-nitrosourea-induced retinal degeneration in mice is independent of the p53 gene. Mol Vis. 2009;15:2919-2925.
146. Ali RR, Reichel MB, Kanuga N, et al. Absence of p53 delays apoptotic photoreceptor cell death in the rds mouse. Curr Eye Res. 1998;17(9):917-923.
147. Carter-Dawson LD, LaVail MM. Rods and cones in the mouse retina. II. Autoradiographic analysis of cell generation using tritiated thymidine. J Comp Neurol. 1979;188(2):263-272.